glp 1 antagonist glp-1_analogs [TUSOM The GLP-1 Agonists and Obesity:

To identify beneficiaries with peripheral arterial disease (PAD), we used ICD-9 diagnosis codes for PAD identified by either Hirsh et al (August 2008) or Jaff et al (July 2010) in their analyses of peripheral arterial disease among Medicare beneficiaries

REFERENCES 1.Gutniak M, Orskov C, Holst JJ, Ahrn B, Efendic S

The phase IIIb clinical trial directly comparing both medications (SURMOUNT-5) is ongoing [38]

The effects of liraglutide on insulin and glucagon secretion are glucose dependent and thus the risk of hypoglycaemia is low

Anyone following a peptide dosing protocol alongside their GLP-1 medication should ensure supplementation does not interfere with other compounds they may be using

JAMA Netw